Janssen Vaccines & Prevention B.V.

🇳🇱Netherlands

Country: 🇳🇱Netherlands

Ownership: -

Established: 2000-01-01

Employees: -

Market Cap: -

Website: http://www.crucell.com

Clinical Trials

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older

Phase 2

Terminated

Conditions: Respiratory Syncytial Viruses
Respiratory Tract Diseases

Interventions: Biological: RSV Vaccine
Biological: Placebo

First Posted Date: 2019-06-11

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 5815

Registration Number: NCT03982199

Locations: 🇺🇸
Rapid Medical Research, Cleveland, Ohio, United States
🇺🇸
Johnson County Clin-Trials, Lenexa, Kansas, United States
🇺🇸
Lynn Institute, Colorado Springs, Colorado, United States

and more 19 locations

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals

Phase 3

Completed

Conditions: Healthy

Interventions: Biological: Ad26.Mos4.HIV
Biological: Placebo
Biological: Clade C and Mosaic gp140 HIV bivalent vaccine

First Posted Date: 2019-05-28

Last Posted Date: 2024-07-31

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 3900

Registration Number: NCT03964415

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Dana-Farber/Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Seattle Vaccine Trials Unit, Seattle, Washington, United States

and more 50 locations

A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants

Phase 2

Completed

Conditions: Ebola Virus Disease

Interventions: Biological: Ad26.ZEBOV
Biological: MVA-BN-Filo
Biological: MenACWY

First Posted Date: 2019-04-29

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 108

Registration Number: NCT03929757

Locations: 🇬🇳
Centre National de Formation et de Recherche en Sante Rurale de Maferinyah, Conakry, Guinea
🇸🇱
College of Med and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone

A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: Ad26.RSV.preF

First Posted Date: 2019-01-07

Last Posted Date: 2019-08-30

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 24

Registration Number: NCT03795441

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Phase 1

Terminated

Conditions: Human Papillomavirus Infections

Interventions: Biological: Ad26.HPV16
Biological: Placebo
Biological: Ad26.HPV18
Biological: MVA.HPV16/18

First Posted Date: 2018-08-01

Last Posted Date: 2025-02-04

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 9

Registration Number: NCT03610581

Locations: 🇺🇸
Medpharmics, LLC, Metairie, Louisiana, United States
🇺🇸
VGR & NOCCR - Knoxville, Knoxville, Tennessee, United States
🇺🇸
Clinical Physiology Associates, Fort Myers, Florida, United States

and more 9 locations

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

Phase 1

Completed

Conditions: Respiratory Syncytial Virus

Interventions: Biological: Ad26.RSV.preF
Biological: Placebo
Biological: Nimenrix

First Posted Date: 2018-07-31

Last Posted Date: 2025-02-04

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 38

Registration Number: NCT03606512

Locations: 🇧🇷
Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil
🇧🇷
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS, Porto Alegre, Brazil
🇫🇮
Turun rokotetutkimusklinikka, Turku, Finland

and more 22 locations

A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule

Phase 2

Completed

Conditions: Healthy

Interventions: Biological: sIPV
Biological: cIPV

First Posted Date: 2018-06-25

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 302

Registration Number: NCT03566940

Locations: 🇵🇭
De La Salle Health Sciences Institute- DLSUMC, Dasmarinas, Philippines
🇵🇭
Philippine General Hospital, Manila, Philippines
🇵🇭
De La Salle University Medical Center, Dasmarinas, Philippines

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: Placebo
Biological: RSV preF Protein 150 mcg
Biological: Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg
Biological: Selected Regimen
Biological: RSV preF Protein 50 mcg
Biological: Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg
Biological: Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg
Biological: Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg
Biological: Ad26.RSV.preF 1*10^11 vp

First Posted Date: 2018-04-19

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 669

Registration Number: NCT03502707

Locations: 🇺🇸
Optimal Research, Austin, Texas, United States

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: Ad26.ZIKV.001 5*10^10 vp
Biological: Ad26.ZIKV.001 1*10^11 vp
Biological: Placebo

First Posted Date: 2017-11-29

Last Posted Date: 2019-10-15

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 100

Registration Number: NCT03356561

Locations: 🇺🇸
Johnson County Clinical Trials, Lenexa, Kansas, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

Phase 2

Completed

Conditions: Healthy

Interventions: Biological: Ad26.RSV.preF
Biological: Fluarix
Biological: Placebo

First Posted Date: 2017-11-13

Last Posted Date: 2025-02-04

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 180

Registration Number: NCT03339713

Locations: 🇺🇸
Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States

Home Terms & Conditions Privacy Policy